Tourmaline Bio, Inc.: restructuring charge — Talaris discontinues kidney transplant trials, cuts 1/3 of staff, explores strategic alternatives

Tourmaline Bio, Inc.

Discontinues FREEDOM-1 and FREEDOM-2 kidney transplant trials due to slow enrollment; continues FREEDOM-3 scleroderma trial.
Workforce reduced by ~1/3; remaining employees focus on cell therapy CMC and FREEDOM-3 trial.
Expects ~$2.9M in restructuring costs in Q1-Q2 2023; cash position ~$181.3M as of Dec 31, 2022.
Initiates comprehensive strategic review including possible business combinations or divestiture of cell therapy CMC.
No timetable set for strategic review; suspends further program guidance.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.95

Tourmaline Bio, Inc. announced a restructuring with charges of approximately $2.9 million for retention, severance and other employee termination-related costs affecting workforce reduction by approximately one-third (reducing the Company's workforce by approximately one-third).

Type: restructuring
Charge: approximately $2.9 million for retention, severance and other employee termination-related costs
Affected area: workforce reduction by approximately one-third
Headcount: reducing the Company's workforce by approximately one-third

Exact text from the filing

clinical development programs and further prioritization of the Company’s resources as it assesses strategic alternatives. The Company estimates that it will incur approximately $2.9 million for retention, severance and other employee termination-related costs in the first and second quarters of 2023. The estimate of costs that the Company expects to incur and the

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001193125-23-040697

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.